Back to today’s briefing

Story perspectives

New Treatments Revolutionize Prostate Cancer Care for Patients

1/30/2025

41 8

Summary

Story summary

A 67-year-old man battling recurrent metastatic prostate cancer is pursuing aggressive treatment options. The promising ARANOTE study reveals that combining darolutamide with androgen deprivation therapy greatly enhances radiographic progression-free survival. Meanwhile, the innovative MyProstateScore 2.0 test offers a non-invasive way to assess aggressive cancer risk, paving the way for more personalized and effective prostate cancer care.

1 of 1

Story summary

A 67-year-old man battling recurrent metastatic prostate cancer is pursuing aggressive treatment options. The promising ARANOTE study reveals that combining darolutamide with androgen deprivation therapy greatly enhances radiographic progression-free survival. Meanwhile, the innovative MyProstateScore 2.0 test offers a non-invasive way to assess aggressive cancer risk, paving the way for more personalized and effective prostate cancer care.